MAI Capital Management Has $8.63 Million Position in Becton, Dickinson and Company (NYSE:BDX)

MAI Capital Management lowered its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 6.5% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 35,812 shares of the medical instruments supplier's stock after selling 2,470 shares during the quarter. MAI Capital Management's holdings in Becton, Dickinson and Company were worth $8,634,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Livelsberger Financial Advisory acquired a new position in Becton, Dickinson and Company in the 3rd quarter valued at $26,000. Ashton Thomas Securities LLC acquired a new position in Becton, Dickinson and Company in the 3rd quarter valued at $33,000. Tompkins Financial Corp raised its holdings in Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier's stock valued at $36,000 after acquiring an additional 46 shares during the last quarter. Sound Income Strategies LLC raised its holdings in Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier's stock valued at $40,000 after acquiring an additional 44 shares during the last quarter. Finally, Opal Wealth Advisors LLC acquired a new position in Becton, Dickinson and Company in the 2nd quarter valued at $45,000. Hedge funds and other institutional investors own 86.97% of the company's stock.

Analysts Set New Price Targets

Several research analysts have weighed in on BDX shares. Raymond James cut their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an "outperform" rating for the company in a report on Friday, August 2nd. StockNews.com raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Thursday, August 8th. Citigroup raised shares of Becton, Dickinson and Company from a "neutral" rating to a "buy" rating and increased their price target for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Evercore ISI increased their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 1st. Finally, Stifel Nicolaus raised their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a "buy" rating in a research note on Friday, July 26th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $283.00.

Becton, Dickinson and Company Trading Down 0.7 %

Becton, Dickinson and Company stock traded down $1.46 during midday trading on Tuesday, reaching $222.64. The stock had a trading volume of 1,379,180 shares, compared to its average volume of 1,409,833. The firm's fifty day simple moving average is $236.03 and its two-hundred day simple moving average is $234.89. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $249.89. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. The firm has a market cap of $64.35 billion, a price-to-earnings ratio of 37.37, a PEG ratio of 1.68 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the prior year, the firm earned $3.42 EPS. The company's revenue was up 6.9% compared to the same quarter last year. Equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be given a $1.04 dividend. The ex-dividend date of this dividend is Monday, December 9th. This is a positive change from Becton, Dickinson and Company's previous quarterly dividend of $0.95. This represents a $4.16 dividend on an annualized basis and a yield of 1.87%. Becton, Dickinson and Company's payout ratio is 63.97%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.